AROMATASE-ACTIVITY AND ESTRADIOL IN HUMAN BREAST-CANCER - ITS RELATIONSHIP TO ESTRADIOL AND EPIDERMAL GROWTH-FACTOR RECEPTORS AND TO TUMOR-NODE-METASTASIS STAGING

Purpose: The present report attempts to clarify whether there is a relationship between aromatase activity (ARAC) and estradiol (EJ, hormonal receptors, E, receptor (ER), and epidermal growth factor receptor (EGFR), as well as with tumor stage and histopathology in human breast cancers. Materials and Methods: We studied 225 breast carcinomas, 67 of which were premenopausal and 158 postmenopausal. In each sample, ARAC, EGFR, ER, and E2 were quantified. ARAC was quantified by Thompson and Siiterii's method, EGFR was quantified with a two-point assay method using radioactive iodine (125I)-EGF as ligand, and ER was measured by the Scatchard method using 3H-E2. E2 was quantified by radioimmunoassay in the diethylether tumor extract. Results: ARAC was found in 64% of the cancers studied. There is a strong direct association between ARAC and tumor size in postmenopausal patients (P = .001). In the postmenopausal group, the proportion of ARAC-positive (ARAC+) tumors is significantly higher among ER-positive (ER+)than ER-negative (ER-) ones (P < .001). ER+ tumors also have significantly higher levels of E2 than do ER- ones (P < .0001); similarly, ARAC+ tumors have significantly higher levels of E2, than do ARAC- ones (P < .0001). There is a significant multiple linear correlation between the log of the levels of ARAC, ER, and EGFR and the log of tumor E2 (P < .0001). The correlation coefficients obtained show that ARAC and ER have a positive effect on tumor E2. Conclusion: The results obtained suggest the importance of tumor ARAC in the tumoral levels of E2 and reinforce the possible biologic significance of tumor ARAC, especially in postmenopausal breast carcinoma patients. © 1992 by American Society of Clinical Oncology.